Tessa Romero
Stock Analyst at JP Morgan
(1.85)
# 1222
Out of 5,270 analysts
61
Total ratings
47.62%
Success rate
32.16%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Upstream Bio | Initiates Coverage On: Overweight | 38 | 7.41 | 412.82% | 1 | Nov 5, 2024 | |
Neumora Therapeutics | Downgrades: Neutral | 18 15 | 1.42 | 956.34% | 4 | Nov 5, 2024 | |
Dyne Therapeutics | Downgrades: Neutral | 43 35 | 12.29 | 184.78% | 4 | Oct 24, 2024 | |
Seres Therapeutics | Downgrades: Underweight | n/a | n/a | n/a | 2 | Oct 24, 2024 | |
Scholar Rock Holding | Maintains: Overweight | 18 31 | 36.24 | -14.46% | 5 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 55 68 | 31.93 | 112.97% | 5 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 71 | 42.92 | 65.42% | 4 | Sep 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 29 | 5.72 | 406.99% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 31 | 25.47 | 21.71% | 8 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reinstates: Neutral | 46 | 33.17 | 38.68% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 29 25 | 18.14 | 37.82% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 2.37 | 743.88% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 8 7 | 5.2 | 34.62% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 54 55 | 35.7 | 54.06% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 39 36 | n/a | n/a | 4 | Jun 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 140 150 | n/a | n/a | 1 | Mar 2, 2021 |